share_log

洛陽鉬業：董事會召開日期

CMOC: DATE OF BOARD MEETING

香港交易所 ·  Mar 12 06:20
Summary by Moomoo AI
洛陽欒川鉬業集團股份有限公司（簡稱「CMOC」，股份代號：03993）將於2024年3月22日（星期五）召開董事會會議。會議的主要議程包括考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績，以及建議派發末期股息。此外，會議還將處理其他事項。董事會由執行董事孫瑞文先生及李朝春先生，非執行董事袁宏林先生、林久新先生及蔣理先生，以及獨立非執行董事王友貴先生、嚴冶女士及李樹華先生組成。
洛陽欒川鉬業集團股份有限公司（簡稱「CMOC」，股份代號：03993）將於2024年3月22日（星期五）召開董事會會議。會議的主要議程包括考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績，以及建議派發末期股息。此外，會議還將處理其他事項。董事會由執行董事孫瑞文先生及李朝春先生，非執行董事袁宏林先生、林久新先生及蔣理先生，以及獨立非執行董事王友貴先生、嚴冶女士及李樹華先生組成。
Luoyang Luanchuan Molybdenum Group Co., Ltd. (abbreviated as “CMOC”, stock code: 03993) will hold a Board meeting on Friday, March 22, 2024. THE MAIN AGENDA OF THE MEETING INCLUDES CONSIDERATION AND APPROVAL OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED 31 DECEMBER 2023 AND THE PROPOSED DISTRIBUTION OF A FINAL DIVIDEND. In addition, the meeting will deal with other matters. The Board of Directors is composed of Executive Directors Mr. Sun Ruiwen and Mr. Lee Chaochun, Non-Executive Directors Mr. Yuan Honglin, Mr. Lin Jiu-xin and Mr. Jiang Li, and Independent Non-Executive Directors Mr. Wang Youkui, Ms. Yan Yi and Mr. Li Shu-hua.
Luoyang Luanchuan Molybdenum Group Co., Ltd. (abbreviated as “CMOC”, stock code: 03993) will hold a Board meeting on Friday, March 22, 2024. THE MAIN AGENDA OF THE MEETING INCLUDES CONSIDERATION AND APPROVAL OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED 31 DECEMBER 2023 AND THE PROPOSED DISTRIBUTION OF A FINAL DIVIDEND. In addition, the meeting will deal with other matters. The Board of Directors is composed of Executive Directors Mr. Sun Ruiwen and Mr. Lee Chaochun, Non-Executive Directors Mr. Yuan Honglin, Mr. Lin Jiu-xin and Mr. Jiang Li, and Independent Non-Executive Directors Mr. Wang Youkui, Ms. Yan Yi and Mr. Li Shu-hua.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more